Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 375

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 375
---
 2,433 |     |            |  22 |     |            | — |     |            |  2,455 |
| Total marketable securities           |     |                         | 28,087 |     |            | 225 |     |            | — |     |            | 28,312 |
| Total cash equivalents and marketable |     | $                       | 38,487 |     | $          | 274 |     | $          | — |     | $          | 38,761 |

The contractual maturities of the Company’s marketable securities are summarized as follows (in thousands):

|                              |     | As of December 31, 2024 |       |     |            |     |     |            |   |     |            |       |
|:-----------------------------|:----|:------------------------|------:|:----|:-----------|----:|:----|:-----------|:--|:----|:-----------|------:|
|                              |     | Amortized               
 Cost                    |       |     | Unrealized 
 Gains      |     |     | Unrealized 
 Losses     |   |     | Aggregate  
 Fair Value |       |
| Within one year              |     | $                       | 4,910 |     | $          | 111 |     | $          | — |     | $          | 5,021 |
| After one year to five years |     |                         |     — |     |            |   — |     |            | — |     |            |     — |
| Total marketable securities  |     | $                       | 4,910 |     | $          | 111 |     | $          | — |     | $          | 5,021 |

As of December 31, 2024 and 2023, there were no available-for-salesecurities that have been in a continuous unrealized loss position for more than 12 months. F-19

LB Pharmaceuticals Inc Notes to Financial Statements A reconciliation of the cash, cash equivalents and restricted cash reported in the balance sheets that sum to the total of the amounts shown in the statements of cash flows is as follows (in thousands):

|                                                  |     | As of December 31, |   2024 |     |   |   2023 |
|:-------------------------------------------------|:----|:-------------------|-------:|:----|:--|-------:|
| Cash and cash